Follow-up of thrombin generation after prostate cancer surgery: Global test for increased hypercoagulability - Abstract

Recent studies provided evidence that evaluation of thrombin generation identifies patients at thrombotic risk.

Thrombin generation has a central role in hemorrhage control and vascular occlusion and its measurement provides new metrics of these processes providing sufficient evaluation of an individual's hemostatic competence and response to anticoagulant therapy. The objective of the study is to assess a new measure of hypercoagulability that predisposes to venous thromboembolism in the postoperative period after radical prostatectomy. Pre- (day-1) and postoperative (hour 1, day 6, month 1 and 10) blood samples of 24 patients were tested for plasma thrombin generation (peak thrombin), routine hematology and hemostasis. Patients received low molecular weight heparin for thromboprophylaxis. Peak thrombin levels were higher in patients compared to controls at baseline (p< 0.001), and elevated further in the early postoperative period (p< 0.001). Longer general anesthesia and high body mass index were associated with increased thrombin generation after surgery (p = 0.024 and p = 0.040). D dimer and fibrinogen levels were higher after radical prostatectomy (p = 0.001 and p< 0.001). Conventional clotting tests remained within the reference range. Our study contributed to the cognition of the hypercoagulable state in cancer patients undergoing pelvic surgery and revealed the course of thrombin generation after radical prostatectomy. Whilst it is unsurprising that thrombin generation increases after tissue trauma, further evaluation of this condition during the postoperative period would lead urologists to an international and well-supported consensus regarding thromboprophylaxis in order to provide better clinical outcome. Considering the routine evaluation of procoagulant activity and extending prophylactic anticoagulant therapy accordingly may potentially prevent late thrombotic events.

Written by:
Benyo M, Flasko T, Molnar Z, Kerenyi A, Batta Z, Jozsa T, Harsfalvi J.   Are you the author?
Department of Urology, Medical and Health Science Center, University of Debrecen, Hungary.

Reference: PLoS One. 2012;7(12):e51299.
doi: 10.1371/journal.pone.0051299

PubMed Abstract
PMID: 23236465 Prostate Cancer Section